ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Published on 2 Dec 2024 on Zacks

Free Report) announced that it has filed new drug submissions (NDSs) in Canada to seek approval for...

Read the rest of the article

Start tracking your investments with Statfolio

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with...

Zacks · via Yahoo Finance 19 Dec 2024

Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408,...

Zacks · via Yahoo Finance 14 Dec 2024

Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its...

Zacks · via Yahoo Finance 13 Dec 2024

Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 9 Dec 2024

Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 6 Dec 2024

Some other top-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 4 Dec 2024

Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reduci...

Zacks · via Yahoo Finance 4 Dec 2024

Free Report) announced that it has filed new drug submissions (NDSs) in Canada to seek approval f...

Zacks 2 Dec 2024

MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The...

Zacks · via Yahoo Finance 29 Nov 2024

Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 29 Nov 2024